Intrathecal drug delivery systems may be ineffective in reducing pain and oral opioid intake in individuals with complex regional pain syndrome.
The Company indicated that they will work towards an New Drug Application submission for the treatment in the second half of 2018.
The use of liposomal bupivacaine after total knee arthroplasty with a peripheral nerve block may not result in reductions in inpatient intake of opioids, hospital length of stay, or opioid-related complications.
For patients undergoing autologous breast reconstruction, the incidence of chronic postsurgical pain does not differ for patients receiving transversus abdominis plane catheters delivering bupivacaine or saline bolus.
Clinical Pain Advisor Articles
- Replacing Sleep, Sedentary Behavior With Physical Activity Beneficial in Knee Osteoarthritis
- The Role of Psychological Factors in Phantom Limb Pain Reviewed
- FDA Outlines Plan for New Analgesic Guidance to Combat Opioid Crisis
- Ozone vs Corticosteroids May Provide Longer-Lasting Effects for Plantar Fasciitis
- Opioid Use Stable in Past Decade Among Commercially Insured, Medicare Beneficiaries
- Ketamine: Mechanisms of Action, Uses in Pain Medicine, and Side Effects
- Cannabis May Be Effective for Migraine Treatment
- Medicinal Cannabis May Not Have Opioid-Sparing Effects in Chronic Noncancer Pain
- Integrating Psychological Interventions Into Chronic Pain Management
- Chronic Neck Pain: Generators, Clinical Examination, MRI Findings, and Differential Diagnosis
- Pregabalin May Not Improve Analgesia During Medical Abortion
- Investigational Treatment Shows Promise in Chronic Low Back Pain
- Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD
- Pain Severity May Partly Mediate the Association Between Depression and Physical Performance in Knee OA